eli lilly glp-1 agonist Lilly's retatrutide, a GIP/GLP-1/glucagon triple agonist, met Phase 3 endpoints, delivering 28.3% weight loss over 80 weeks in TRIUMPH-1. # EliLilly #Retatrutide #GLP1 #GIP #Glucagon #ObesityTreatment #Phase3 #TRIUMPH1 #WeightLossDrugs Discovery of GLP-1–Based Drugs Sample collection:Walk-in clinic YGroup_weightloss

eli lilly glp-1 agonist Lilly's retatrutide, a GIP/GLP-1/glucagon triple agonist, met Phase 3 endpoints, delivering 28.3% weight loss over 80 weeks in TRIUMPH-1. # EliLilly #Retatrutide #GLP1 #GIP #Glucagon #ObesityTreatment #Phase3 #TRIUMPH1 #WeightLossDrugs Discovery of GLP-1–Based Drugs Sample collection:Walk-in clinic YGroup_weightloss

Discovery of GLP-1–Based Drugs for the Treatment of Obesity | New England Journal of Medicine

Evidence Supporting a Beneficial Effect of GLP-1 Receptor Agonists on Erectile Function While high-quality clinical data remain limited, accumulating evidence increasingly supports a potential therapeutic role for GLP-1 RAs in the management of ED

YGroup_weightloss

Sample collection:Walk-in clinic

LHA, lateral hypothalamic area